Cancer Biotech Phio Pharmaceuticals Stock Surges As Trial Shows Tumor Clearance At Highest Dose In Skin Cancer Patients

1 hour ago 1

Phio Pharmaceuticals shares emergence aft Phase 1b information shows beardown information and tumor clearance for its PH-762 tegument crab drug, with FDA talks planned successful 2026.

Importance Rank: